Table 1.
Characteristics of HPV VLP vaccines
| Manufacturer | Merck™ (Gardasil®) | GlaxoSmithKline™ (Cervarix®) | Merck™ (Gardasil® 9) |
|---|---|---|---|
| L1 VLP types | 6, 11, 16, and 18 | 16 and 18 | 6, 11, 16, 18, 31, 33, 45, 52, and 58 |
| Dose | 20/40/40/20 µg | 20/20 µg | 30/40/60/40/20/20/20/20/20 µg |
| Producer cells | Saccharomyces cerevisiae (baker’s yeast) expressing L1 | Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus | Saccharomyces cerevisiae (baker’s yeast) expressing L1 |
| Adjuvant | 225 µg aluminium hydroxyphosphate sulfate | 500 µg aluminium hydroxide, 50 µg 3-O-deacylated-4ʹ-monophosphoryl lipid A | 500 µg aluminium hydroxyphosphate sulfate |
| Vaccination schedule | 0, 2, and 6 months | 0, 1, and 6 months | 0, 2, and 6 months |
Abbreviations: HPV, human papillomavirus; VLP, virus-like particle.